Investigational Respiratory Syncytial Virus Vaccine Study

AMR Kansas City is now enrolling healthy adults 60 to 85 in an investigational Respiratory Syncytial Virus (RSV) vaccine study.

Qualified participants must:

have received an AREXVY vaccine at least 18 months before study enrollment

meet other study criteria

Qualified participants will receive all study-related care at no cost. Reimbursement is available up to $730.00 for study-related time and travel.

If you're interested in learning more about this trial, you can reach out to AMR today by calling 816-643-4153 or visiting their website at www.amrkansascity.com for more detailed information.